Join
Live feed
·
PRReleasevia Quantisnow
Jyong Biotech Ltd. logo

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

ByQuantisnow·Wall Street's wire, on your screen.
MENS· Jyong Biotech Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MENS (Jyong Biotech Ltd.) and more on Quantisnow.